HK Stock Market Move | CARSGEN-B (02171) rose more than 3% in the afternoon, planning to repurchase up to 5% of the company's shares.

CARSGEN-B (02171) rose more than 3% in the afternoon, up 2.9% at the time of publication, at HK$12.78, with a turnover of HK$96.0851 million. On the news front, KJ Pharmaceuticals announced at noon that the board of directors has approved a share repurchase plan, to repurchase no more than approximately 30.12 million shares on the open market from June 25, 2026, until the end of the next annual general meeting of shareholders, equivalent to about 5% of the total number of shares issued as of May 31, 2026. The funds for the share repurchase come from non-IPO fundraising, including business development revenue, interest income, and other subsidies. Recently, KJ Pharmaceuticals announced that their self-developed Claudin18.2 autologous CAR-T cell therapy product, Kailimei (Sulitrexed injection), has been approved for market application by the National Medical Products Administration. The official price of Kailimei is set at 990,000 yuan per person, taking into account the pricing of other CAR-T products on the market, epidemiology, and payment factors.